Press release
Progressive Multifocal Leukoencephalopathy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics,
Progressive Multifocal Leukoencephalopathy Clinical Trials
DelveInsight reports that over three key companies are actively developing more than three therapeutic candidates for Progressive Multifocal Leukoencephalopathy (PML).
Progressive Multifocal Leukoencephalopathy Overview:
Progressive multifocal leukoencephalopathy (PML) is a rare and often life-threatening brain infection. It can occur as a complication of certain medications for multiple sclerosis and other autoimmune disorders, or in individuals with HIV or specific blood and lymphatic cancers. The condition is caused by the John Cunningham (JC) virus, a polyomavirus that remains dormant in the kidneys and bone marrow of more than 60% of adults. PML develops when the virus is reactivated due to prolonged or drug-induced immune suppression, allowing it to invade the brain. This results in irreversible brain damage, severe cognitive and motor impairments, and a high risk of death. Currently, there are no approved therapies for treating PML.
Request for a detailed insights report on Progressive Multifocal Leukoencephalopathy pipeline insights [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Progressive Multifocal Leukoencephalopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Progressive Multifocal Leukoencephalopathy Therapeutics Market.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Pipeline Report
*
DelveInsight's Progressive Multifocal Leukoencephalopathy (PML) pipeline report highlights an active landscape with over three companies developing more than three therapeutic candidates for PML.
*
Leading players such as Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics, I-MAB Biopharma, and others are advancing novel therapies to improve treatment options for PML.
*
Promising candidates in various stages of development include NT-I7, IkT-01427, and others.
*
In October 2022, Cellevolve Bio received FDA clearance for its IND application and Orphan Drug Designation for CE-VST01-JC, an allogeneic, off-the-shelf T cell therapy targeting the JC virus, which causes PML. The company plans to initiate ASCEND-JC, a Phase 2 placebo-controlled trial evaluating the therapy's safety and efficacy, with first patient enrollment expected in the first half of 2023.
*
Earlier, in June 2020, the FDA granted Orphan Drug Designation to NT-I7, a long-acting human interleukin-7 (IL-7), for PML treatment. Subsequently, in February 2021, NeoImmuneTech received FDA clearance for an IND application to begin a pilot study assessing NT-I7's safety and efficacy in PML patients.
Progressive Multifocal Leukoencephalopathy Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Progressive Multifocal Leukoencephalopathy Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Progressive Multifocal Leukoencephalopathy treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Progressive Multifocal Leukoencephalopathy market.
Download our free sample page report on Progressive Multifocal Leukoencephalopathy pipeline insights [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Emerging Drugs
*
NT-I7: NeoImmuneTech
*
IkT-01427: Inhibikase Therapeutics
Progressive Multifocal Leukoencephalopathy Companies
Over three leading companies are engaged in developing therapies for Progressive Multifocal Leukoencephalopathy (PML), with NeoImmuneTech advancing the most progressed candidates, currently in Phase I clinical trials.
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Progressive Multifocal Leukoencephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Progressive Multifocal Leukoencephalopathy Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Progressive Multifocal Leukoencephalopathy Therapies and Key Companies: Progressive Multifocal Leukoencephalopathy Clinical Trials and advancements [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Pipeline Therapeutic Assessment
- Progressive Multifocal Leukoencephalopathy Assessment by Product Type
- Progressive Multifocal Leukoencephalopathy By Stage
- Progressive Multifocal Leukoencephalopathy Assessment by Route of Administration
- Progressive Multifocal Leukoencephalopathy Assessment by Molecule Type
Download Progressive Multifocal Leukoencephalopathy Sample report to know in detail about the Progressive Multifocal Leukoencephalopathy treatment market @ Progressive Multifocal Leukoencephalopathy Therapeutic Assessment [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Progressive Multifocal Leukoencephalopathy Current Treatment Patterns
4. Progressive Multifocal Leukoencephalopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Progressive Multifocal Leukoencephalopathy Late-Stage Products (Phase-III)
7. Progressive Multifocal Leukoencephalopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Progressive Multifocal Leukoencephalopathy Discontinued Products
13. Progressive Multifocal Leukoencephalopathy Product Profiles
14. Progressive Multifocal Leukoencephalopathy Key Companies
15. Progressive Multifocal Leukoencephalopathy Key Products
16. Dormant and Discontinued Products
17. Progressive Multifocal Leukoencephalopathy Unmet Needs
18. Progressive Multifocal Leukoencephalopathy Future Perspectives
19. Progressive Multifocal Leukoencephalopathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Progressive Multifocal Leukoencephalopathy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=progressive-multifocal-leukoencephalopathy-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-inhibikase-therapeutics-neurimmune-excision-biotherapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Multifocal Leukoencephalopathy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics, here
News-ID: 4160506 • Views: …
More Releases from ABNewswire
From London Comforts to Vietnamese Chaos: Author Jane Roberts Unveils the Gritty …
When a high-stakes job offer in Hanoi disrupts a settled life in the UK, one woman abandons her safety net to build a market-leading empire amidst humidity, hardship, and the unknown-proving that true transformation only happens when you stop playing it safe.
In her powerful debut, Follow Your Dreams: Dare to Venture into the Unknown, Jane Roberts brings us a compelling narrative about the transformative power of chasing your dreams, even…
Mount Pleasant Chiropractic Practice Now Accepting New Patients for Advanced Pla …
Integra Health, led by Dr. Noble Thomas, DC, MSACN, has launched a specialized treatment protocol for residents seeking plantar fasciitis treatment in Mount Pleasant, NY. This comprehensive, non-surgical approach combines chiropractic care, shockwave therapy, and functional rehabilitation to address the root causes of chronic heel pain. By focusing on the whole kinetic chain, Integra Health provides Westchester County patients with a drug-free path to improved mobility and long-term relief.
MOUNT PLEASANT,…
Southlake Primary Care Clinic Offering Hormone Replacement Therapy to Help Patie …
Southlake's Elixir 360 Health expands its services with Bioidentical Hormone Replacement Therapy (BHRT) for men and women. Addressing symptoms like fatigue, weight gain, and mental fog, the practice offers personalized, plant-based hormone protocols molecularly identical to the body's natural chemistry. Led by Raj Agarwal, Elixir 360 Health provides DFW residents with advanced regenerative medicine and customized care to restore vitality and hormonal balance.
SOUTHLAKE, Texas - December 19, 2024 - Elixir…
DermaStation Skin Clinic strengthens its hair loss treatment offering
The Delhi-based skin clinic offers the most advanced hair loss treatment that ensures healthier hair regrowth and improved density.
In view of the growing concerns over progressive hair fall and pattern baldness, DermaStation, a popular dermatology clinic in Delhi, enhances its Platelet Rich Plasma Therapy for better and lasting results.
The move to offer advanced platelet rich plasma treatment [https://www.dermastation.com/blog/platelet-rich-plasma-treatment-in-delhi-a-complete-guide-to-prp-therapy/] and comprehensive treatment is in line with DermaStation's commitment to provide finest…
More Releases for Progressive
Progressive Insurance Market Is Booming So Rapidly | Major Giants Progressive Co …
HTF MI just released the Global Progressive Insurance Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Key Players in This Report Include:
Progressive Corporation, State Farm, Allstate, GEICO,…
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is…
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
• According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4…
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400…
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
